Knopp Kevin J. sold $2K of MASS

Knopp Kevin J. (President and CEO) sold 222 shares of 908 Devices Inc. (MASS) at $9.07 on 2026-07-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Knopp Kevin J.
Published Jul 7, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 7, 2026, 8:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MASS
Neutral
high confidence
Mentioned
$MASS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MASSNeutralLow
01

Why it matters

The CEO’s open-market sale under a 10b5-1 plan is typically treated as routine compliance rather than a new fundamental catalyst.

02

Market read

Traders may note the insider sale for sentiment, but the small size and 10b5-1 structure reduce expected impact.

03

What to watch

The transaction value is very small and the sale is explicitly pre-arranged, which often makes it less informative than discretionary sales.

Relevance 2/10Novelty 3/10Timing: New Form 4 filed 2026-07-07 (after-hours) disclosing the 2026-07-02 sale.

Background

The article is an SEC Form 4 insider transaction report for 908 Devices Inc. (MASS).

Company-level read

Ticker impact

$MASSNeutralHigh confidence
Context

SEC Form 4 shows MASS CEO sold 222 shares on 2026-07-02 at $9.0700/share under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a small-value open-market sale (~$2.0k) by the CEO with an explicit 10b5-1 plan, which typically reduces interpretive signal.

Market effects

No sector read-across; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted as confidence erosion by some traders.

Key entities

  • 908 Devices Inc.

    Company whose CEO filed the Form 4 disclosing an open-market sale of shares.

  • Knopp Kevin J.

    President and CEO who sold 222 shares at $9.0700/share under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MASSHigh

908 Devices Inc (MASS) (Q3 2026) Earnings Call Highlights: Record $19 Million Revenue

908 Devices Inc (MASS) reported Q3 2026 revenue of $19M, up 35% YoY, driven by FTIR products and NearLab sales. The company raised full-year revenue guidance to $68.5M-$70M. Adjusted EBITDA loss narrowed to $1.7M, but gross margin decreased to 58%. MASS shipped 300+ devices, bringing the installed base to 4,400. NearLab integration is progressing, with 100 devices sold in Q3. The company remains unprofitable, with a net loss of $4.6M and $2.4M cash burn.

$MASSMed

908 Devices Q3 2026 slides: 35% growth, raised guidance

908 Devices (NASDAQ:MASS) reported 35% YoY revenue growth to $19.0M in Q3 2026, raising full-year guidance to $68.5M-$70.0M. Shares fell 4.43% premarket. The company focuses on chemical detection tools for public safety and defense, with FTIR products contributing 55% of revenue. Despite narrowing losses, concerns remain over customer concentration and adjusted EBITDA losses.

$MASSMed

908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue

908 Devices Inc. (MASS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ 908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue Revenue increased 35% compared to prior year Raises low end of 2026 revenue outlook ​ ​ BURLINGTON, Mass. – November 10, 2026 – 908 Devices Inc. (Nasdaq: MASS), a core small-cap

$MASSMed

908 Devices Inc. Q2 2026 Earnings Call Summary

908 Devices reported Q2 2026 revenue up 23%, driven by U.S. state and local demand for fentanyl and synthetic drug detection. VipIR saw 35+ shipments, and the NIRLAB acquisition added an AI subscription model. Full-year 2026 revenue guidance was raised to $68m-$70m. Adjusted EBITDA loss narrowed 50% YoY; recurring revenue target is 30%+.

$MASSMedAI 8/10

908 Devices Q2 Earnings Call Highlights

908 Devices (NASDAQ: MASS) reported Q2 operating expenses of $21.2M, down from $21.5M, and narrowed net loss from continuing operations to $11.9M. Adjusted EBITDA loss improved to $1.9M. Cash and marketable securities were $101.5M with no debt. The company raised 2026 revenue guidance to $68M-$70M and expects recurring revenue of $4.9M (31%).